Atazanavir Sulfate; Cobicistat Tablet — FDA Drug Shortage

To Be Discontinued — Bristol Myers Squibb Co.

The FDA lists a drug shortage record for Atazanavir Sulfate; Cobicistat Tablet (tablet) from Bristol Myers Squibb Co. with status To Be Discontinued. The shortage was first posted on 11/03/2025.

Shortage Details

Status
To Be Discontinued
Company
Bristol Myers Squibb Co.
Package NDC
0003-3641-11
Dosage Form
Tablet
Presentation
Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)
Initial Posting
11/03/2025
Revised Date